Q2 2025 Biogen Inc Earnings Call Transcript
Key Points
- Biogen Inc (BIIB) reported 7% revenue growth in the second quarter, driven by strong commercial execution and new product launches.
- The company saw significant growth in its new product launches, with products like VUMERITY, LEQEMBI, SKYCLARYS, and ZURZUVAE showing strong performance.
- Biogen Inc (BIIB) is making progress in its pipeline, with multiple Phase III studies initiated and positive interim data for salanersen in SMA.
- The company is expanding its presence in international markets, with products like SKYCLARYS now available in 29 markets globally.
- Biogen Inc (BIIB) raised its full-year 2025 financial guidance, reflecting a stronger expected business outlook and resilient performance in the US MS business.
- Biogen Inc (BIIB) faces competitive pressures in its ex-US MS business, particularly for TECFIDERA in Europe, due to generic and biosimilar competition.
- The company anticipates increased competitive pressures in the second half of 2025, which may impact revenue growth.
- Biogen Inc (BIIB) is dealing with arbitration related to commercialization allocations in Europe with its partner ASI, indicating potential challenges in partnership dynamics.
- The company expects minimal contract manufacturing revenue in Q4 2025 due to planned plant maintenance activities.
- Biogen Inc (BIIB) acknowledges the need for significant education and real-world evidence to establish blood-based biomarkers as a standard for amyloid confirmation in Alzheimer's diagnosis.
Good morning. My name is Cynthia, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen second quarter 2025 earnings call and business update. (Operator Instructions). Today's conference is being recorded. Thank you.
I would now like to turn the conference over to Mr. Tim Power, Head of Investor Relations. Mr. Power, you may begin your conference.
Thanks, Cynthia, and good morning, everyone. Welcome to Biogen's second quarter 2025 earnings call. During this call, we will make forward-looking statements, which involves risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. We provide a comprehensive list of risk factors in our SEC filings, which I encourage you to review. Our earnings release and other documents related to our results as well as reconciliations between GAAP and non-GAAP results discussed on this call can be found on the Investors section of biogen.com. We've also posted the slide
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
